{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 26 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'The following therapies are not allowed during the entire treatment period (Visit 2-7). In case', 'any of the following is medically indicated during the course of the trial a 4 week wash-out of', 'nintedanib should be observed before their use:', 'Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran,', 'heparin, hirudin etc), or high dose antiplatelet therapy.', 'The following drugs are not allowed during the study treatment except in case of acute', 'exacerbation of IPF or in case of deterioration at the discretion of the investigator (see section', '4.2.2.2):', 'Azathioprine, cyclophosphamide and cyclosporine A must not be taken within 8', 'weeks of visit 1.', 'N-Acetyl Cysteine (NAC). Must not be taken within 2 weeks of visit 1.', 'Prednisone at > 15 mg/day (or > 30 mg every 2 days or equivalent dose of other oral', 'corticosteroid) must not be taken within 2 weeks of visit 1.', '4.2.2.2', 'Concomitant treatments allowed', 'Following medication is allowed if stabilized for at least 8 weeks prior to visit 1: Prednisone', 'if steady dose < 15 mg /day (or < 30 mg every 2 days) or equivalent.', 'In case of acute exacerbations:', 'all suggested medications (e.g. prednisone at high dose, azathioprine, cyclophosphamide,', \"cyclosporine A or NAC) can be freely initiated or increased at Investigator's discretion\", 'except pirfenidone.', 'In case of deterioration of IPF:', 'Prednisone at high dose, azathioprine, cyclophosphamide, cyclosporine A or NAC can be', \"freely initiated or increased at Investigator's discretion except pirfenidone.\", 'A > 10% decrease in the absolute value of FVC% predicted or a >15% decrease in DLco %', 'predicted is considered deterioration (progression of disease). Example: a change from 50%', 'predicted FVC to 40 % predicted FVC represents deterioration.', 'Prophylactic anticoagulation:', 'Prophylactic low dose heparin or heparin flush as needed for maintenance of an indwelling', 'intravenous device (e.g. enoxaparin 4000 I.U. s.c. per day), as well as prophylactic use of', 'antiplatelet therapy (e.g. acetyl salicylic acid up to 325 mg/d, or clopidogrel at 75 mg/d, or', 'equivalent doses of other antiplatelet therapy) should be allowed.', '4.2.2.3', 'Restrictions on diet and life style', 'There are no restrictions on diet and life style other than those required for the exercise', 'testing and spirometry (Appendix 10.1 and Section 5.1.2.3).', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 27 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '4.2.2.4', 'Restrictions regarding women of childbearing potential', 'Women of childbearing potential must use the contraception methods described in', 'Section 3.3.2 and follow the restrictions described in the patient information for nintedanib', '(R18-1289).', '4.3', 'TREATMENT COMPLIANCE', 'Counsel patients on the importance of taking background medication as directed at each visit,', 'as well as reinforcing attendance at pulmonary rehabilitation for those patients assigned to', 'that treatment arm.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}